1 rich Libsyn https://www.libsyn.com 90 600 S&amp;amp;P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt financed acquisitions/share repurchases. S&amp;P Pharma Dose https://www.spglobal.com/ratings/en/research-insights/podcasts/the-sp-pharma-dose <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/14598503/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/14598503